https://doi.org/10.55788/87ab7301
Migraine and adverse pregnancy outcomes share a common pathophysiology [1]. “Roughly 20% of women of childbearing age experience migraine, but the impact of migraine on pregnancy outcomes has not been well understood,” said study author Dr Alexandra Purdue-Smithe (Harvard Medical School, MA, USA) [2]. This is due to a lack of large prospective studies. Her group in Boston used data from 30,555 pregnancies in 19,694 participants of the longitudinal Nurses’ Health Study 2 and estimated associations of confirmed migraine before pregnancy with pre-term delivery (<37 weeks), gestational diabetes mellitus (GDM), gestational hypertension, pre-eclampsia, and low birthweight (<5.5 lbs).
Pre-pregnancy migraine was found in 11% of participants. Compared with women without migraine, they had a 17% higher risk of pre-term delivery (RR 1.17; 95% CI 1.05–1.30), a 28% higher risk of gestational hypertension (RR 1.28; 95% CI 1.11–1.48), and a 40% higher risk of pre-eclampsia (RR 1.40; 95% CI 1.19–1.65). Pre-pregnancy migraine was not associated with low birth weight (RR 0.99; 95% CI 0.85–1.16) or GDM (RR 1.05; 95% CI 0.91–1.22). Migraine with aura may be more strongly associated with pre-eclampsia, as the risk of pre-eclampsia was 51% higher (RR 1.51; 95% CI 1.22–1.88) among migraine patients with aura, and 29% higher among migraine patients without aura (RR 1.29; 95% CI 1.04–1.61), when compared with women without migraine. Aspirin use was associated with a lower risk of adverse pregnancy outcomes among women with migraine.
These associations may overall not be very strong, but women with a history of migraine should be aware of potential pregnancy risks, according to Dr Purdue-Smithe. “Women with migraine may benefit from closer monitoring during pregnancy, so that complications like pre-eclampsia can be identified and managed as soon as possible.”
- Aukes AM, et al. Obstet Gynecol Surv. 2019;74(12):738‒748.
- Purdue-Smithe A, et al. Pre-pregnancy migraine and risk of adverse pregnancy outcomes. S4.003, AAN 2022, 02–07 April, Seattle, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Intranasal zavegepant safe and well tolerated in healthy adults Next Article
Sustained long-term efficacy and safety of satralizumab in NMOSD »
« Intranasal zavegepant safe and well tolerated in healthy adults Next Article
Sustained long-term efficacy and safety of satralizumab in NMOSD »
Table of Contents: AAN 2022
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer’s Disease and Other Dementias
Targeting senescent cells to treat age-related diseases
Cardiorespiratory fitness protects against dementia
Safety and effects of bosutinib in Lewy body dementia
Epilepsy
“Women with epilepsy should be encouraged to breastfeed”
Fenfluramine: possible new treatment for Lennox-Gastaut syndrome
Laser interstitial thermal therapy for refractory epilepsy
Migraine
Migraine may be an important obstetric risk factor
Intranasal zavegepant safe and well tolerated in healthy adults
Telemedicine during COVID-19 pandemic highly appreciated
Multiple Sclerosis
Ublituximab versus teriflunomide in relapsing MS patients
Ketogenic diet may improve disability and quality of life
Favourable additional safety data for ofatumumab
Predicting new T2 lesions using a machine learning algorithm
Evobrutinib reduces volume of slowly expanding lesions
Sustained long-term efficacy and safety of satralizumab in NMOSD
Muscle and Neuro-Muscular Disorders
Ravulizumab in patients with generalised myasthenia gravis
Gene therapy effective in older patients with spinal muscular atrophy
Losmapimod for facioscapulohumeral muscular dystrophy
SRP-9001 for treating patients with Duchenne muscular dystrophy
Cerebrovascular Disease and Stroke
Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out?
Better outcomes with mechanical thrombectomy in elderly stroke patients
Plasma NfL levels associated with cardiovascular risk
Non-invasive vagus nerve stimulation for acute stroke
Parkinson’s Disease
Prasinezumab in Parkinson’s disease: delayed-start analysis of PASADENA trial
IPX203 versus immediate release carbidopa-levodopa
Impact of COVID-19 public health interventions
COVID-19
Cognitive, EEG, and MRI features in COVID-19 survivors
Neurological manifestations of COVID-19 worsen prognosis
New evidence for biological basis of “COVID-19 brain fog”
Related Articles
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy